Patents by Inventor Martin M. Matzuk
Martin M. Matzuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200048716Abstract: MiniVectors and compositions containing MiniVectors that target ovarian cancer genes selected from FOXM1, AKT, CENPA, PLK1, CDC20, BIRC5, AURKB, CCNB1, CDKN3, BCAM-AKT2, CDKN2D-WDFY2, SLC25A6, CIP2A, CD133, ALDH1A1, CD44, SALL4, and/or PRDM16, alone or in any combination, are provided, along with uses in the treatment of ovarian cancer.Type: ApplicationFiled: November 5, 2018Publication date: February 13, 2020Inventors: E. Lynn Zechiedrich, Martin M. Matzuk, Laising Yen, Zhifeng Yu, Lirio Milenka Arevalo-Soliz, Daniel James Catanese, JR., Jonathan Marcus Fogg, Christopher Elbert Coker
-
Publication number: 20140228423Abstract: In embodiments of the present invention, there are methods and compositions related to diagnosis and treatment of serous ovarian cancer. In specific embodiments, the invention encompasses methods related to miR-34c in diagnosis and treatment methods for serous ovarian cancer. In specific embodiments, the invention encompasses treatment methods for pancreatic cancer and other responsive cancers.Type: ApplicationFiled: June 1, 2012Publication date: August 14, 2014Applicant: BAYLOR COLLEGE OF MEDICINEInventors: Martin M. Matzuk, Jaeyeon Kim, Zhifeng Yu
-
Publication number: 20130225503Abstract: Embodiments of the present invention regard TEX14 peptides for cancer treatment. In particular, the TEX14 peptides comprise a GPPX3Y motif. Methods, compositions, and kits are encompassed.Type: ApplicationFiled: September 30, 2010Publication date: August 29, 2013Applicant: Baylor Licnensing GroupInventors: Martin M. Matzuk, Tokuko Iwamori, Michael P. Greenbaum, Lang Ma, Naoki Iwamori
-
Publication number: 20130065949Abstract: The present invention generally concerns methods and compositions for treating and/or preventing cancer with microRNAs. In specific embodiments, the present invention encompasses a particular microRNA, microRNA-31, as useful in cancer therapy and/or prevention. Specific cancers may be treated, including at least ovarian, prostate, urothelial, osteosarcoma, and glioblastoma.Type: ApplicationFiled: October 14, 2010Publication date: March 14, 2013Applicant: Baylor College of MedicineInventors: Martin M. Matzuk, Chad Creighton, Zhifeng Yu, Michael Fountain, Preethi Gunaratne, Matthew A. Anderson
-
Publication number: 20080293116Abstract: Ovary specific proteins O1 180, O1 184 and O1 236, polynucleotides encoding them, antibodies which are immunoreactive with them and vectors and host cells containing O1 180, O1 184 or O1 236 are provided. Also provided are methods for detecting cell proliferative or degenerative disorders of ovarian origin and which are associated with O1 180, O1 184 or O1 236. Further provided are methods for the evaluation of potential contraceptives using the proteins of the invention, as well as methods for the screening for genetic mutations in signaling pathways that are associated with some forms of human infertility or gynecological cancers, also using the proteins/mRNAs/genes of the invention. The proteins/mRNAs/genes of the invention may also be used as markers for identifying primary and metastatic neoplasms of ovarian origin and as indicators of developmental anomalies in prenatal screening procedures.Type: ApplicationFiled: December 14, 2007Publication date: November 27, 2008Inventors: Martin M. Matzuk, Pei Wang
-
Patent number: 7335737Abstract: Ovary specific proteins O1 180, O1 184 and O1 236, polynucleotides encoding them, antibodies which are immunoreactive with them and vectors and host cells containing O1 180, O1 184 or O1 236 are provided. Also provided are methods for detecting cell proliferative or degenerative disorders of ovarian origin and which are associated with O1 180, O1 184 or O1 236. Further provided are methods for the evaluation of potential contraceptives using the proteins of the invention, as well as methods for the screening for genetic mutations in signaling pathways that are associated with some forms of human infertility or gynecological cancers, also using the proteins/mRNAs/genes of the invention. The proteins/mRNAs/genes of the invention may also be used as markers for identifying primary and metastatic neoplasms of ovarian origin and as indicators of developmental anomalies in prenatal screening procedures.Type: GrantFiled: November 9, 2005Date of Patent: February 26, 2008Assignee: Baylor College of MedicineInventors: Martin M. Matzuk, Pei Wang
-
Patent number: 7232678Abstract: The present invention relates to compositions and methods for modulating conception in animals. More particularly, the composition modulates mRNA degradation during gametogenesis and early development. Yet further, the present invention relates to pharmaceutical compositions and methods for modulating diseases of the reproductive organs, such as hyperproliferative diseases.Type: GrantFiled: May 16, 2003Date of Patent: June 19, 2007Assignees: Wyeth, Baylor College of MedicineInventors: Martin M. Matzuk, Yuchen Bai, Wei Yan
-
Patent number: 6995251Abstract: Ovary-specific proteins O1-180, O1-184 and O1-236, polynucleotides encoding them, antibodies which are immunoreactive with them and vectors and host cells containing O1-180, O1-184 or O1-236 are provided. Also provided are methods for detecting cell proliferative or degenerative disorders of ovarian origin and which are associated with O1-180, O1-184 or O1-236. Further provided are methods for the evaluation of potential contraceptives using the proteins of the invention, as well as methods for the screening for genetic mutations in signaling pathways that are associated with some forms of human infertility or gynecological cancers, also using the proteins/mRNAs/genes of the invention. The proteins/mRNAs/genes of the invention may also be used as markers for identifying primary and metastatic neoplasms of ovarian origin and as indicators of developmental anomalies in prenatal screening procedures.Type: GrantFiled: October 28, 1999Date of Patent: February 7, 2006Assignee: BaylorInventors: Martin M. Matzuk, Pei Wang
-
Publication number: 20040254132Abstract: The present invention relates generally to ovary-specific genes (O1-180, O1-184 and O1-236) and the proteins they encode. Also provided are methods for detecting cell proliferative or degenerative disorders in reproductive tissues. Yet further, the invention provides methods for screeing of compounds that interact and/or modulate the expression or activity of the ovary-specific genes. These compounds are possible contraceptive agents and/or fertility agents.Type: ApplicationFiled: August 5, 2004Publication date: December 16, 2004Inventors: Martin M. Matzuk, Xuemei Wu, Pei Wang, Yuchen Bai
-
Patent number: 6737515Abstract: The invention provides recombinant native and mutein forms of human follicle stimulating hormone beta subunit (FSH beta) with characteristic glycosylation patterns which are influential in the metabolic activity of the protein. The invention also provides recombinant mutant forms of the human alpha subunit common to FSH, LH, CG, and TSH, to obtain hormones which also have unique glycosylation patterns. Also provided are recombinant materials to produce these subunits separately or together to obtain complete heterodimeric hormones of regulated glycosylation pattern.Type: GrantFiled: December 8, 2000Date of Patent: May 18, 2004Assignee: Washington UniversityInventors: Irving Boime, Martin M. Matzuk, Jeffrey L. Keene
-
Patent number: 6680174Abstract: The present invention relates to a method of identifying an agent which alters (inhibits, enhances) activity of GDF-9. The method involves combining cells having a receptor for GDF-9 and a gene, wherein expression of the gene is regulated by binding of GDF-9 to the receptor; GDF-9; and an agent to be assessed. The combination produced is maintained under conditions appropriate for binding of GDF-9 to the receptors on the cells. The extent to which binding of GDF-9 to the receptors on the cells occurs is then determined, wherein binding of GDF-9 to the receptor to a lesser or greater extent in the presence of the agent to be assessed than in its absence, is indicative of an agent which alters GDF-9 activity.Type: GrantFiled: April 1, 1999Date of Patent: January 20, 2004Assignee: Baylor College of MedicineInventors: Martin M. Matzuk, Julia A. Elvin, Pei Wang
-
Publication number: 20030235575Abstract: The present invention relates to compositions and methods for modulating conception in animals. More particularly, the composition modulates mRNA degradation during gametogenesis and early development. Yet further, the present invention relates to pharmaceutical compositions and methods for modulating diseases of the reproductive organs, such as hyperproliferative diseases.Type: ApplicationFiled: May 16, 2003Publication date: December 25, 2003Applicants: WYETH, Baylor College of MedicineInventors: Martin M. Matzuk, Yuchen Bai, Wei Yan
-
Publication number: 20030144205Abstract: The present invention relates to compositions and methods for modulating conception in animals. More particularly, the composition modulates protein degradation during gametogenesis and early development.Type: ApplicationFiled: December 20, 2002Publication date: July 31, 2003Inventors: Martin M. Matzuk, Aleksander Rajkovic, Nobuhiro Suzumori, Kathleen H. Burns
-
Patent number: 6548738Abstract: The present invention discloses transgenic mice with inactivating mutations in the endogenous gene for the acetyl-CoA carboxylase-2 isoform of acetyl-CoA carboxylase. Inactivation of acetyl-CoA carboxylase-2 results in mice exhibiting a phenotype of reduced malonyl-CoA levels in skeletal muscle and heart, unrestricted fat oxidation, and reduced fat accumulation in the liver and fat storage cells. As a result, the mice consume more food but accumulate less fat and remain leaner than wild type mice fed the same diet. These results demonstrate that inhibition of ACC2 acetyl-CoA carboxylase could be used to regulate fat oxidation and accumulation for purposes of weight control. The transgenic mice of the instant invention provide a useful animal model to identify such inhibitors and for studying the mechanisms of fat metabolism and weight control.Type: GrantFiled: December 26, 2000Date of Patent: April 15, 2003Assignee: Research Development FoundationInventors: Salih J. Wakil, Martin M. Matzuk, Lutfi Abu-Elheiga
-
Publication number: 20030028912Abstract: The present invention discloses transgenic mice with inactivating mutations in the endogenous gene for the acetyl-CoA carboxylase-2 isoform of acetyl-CoA carboxylase. Inactivation of acetyl-CoA carboxylase-2 results in mice exhibiting a phenotype of reduced malonyl-CoA levels in skeletal muscle and heart, unrestricted fat oxidation, and reduced fat accumulation in the liver and fat storage cells. As a result, the mice consume more food but accumulate less fat and remain leaner than wild type mice fed the same diet. These results demonstrate that inhibition of ACC2 acetyl-CoA carboxylase could be used to regulate fat oxidation and accumulation for purposes of weight control. The transgenic mice of the instant invention provide a useful animal model to identify such inhibitors and for studying the mechanisms of fat metabolism and weight control.Type: ApplicationFiled: August 15, 2002Publication date: February 6, 2003Applicant: Research Development FoundationInventors: Martin M. Matzuk, Lutfi Abu-Elheiga, Salih J. Wakil
-
Publication number: 20020104111Abstract: The present invention discloses transgenic mice with inactivating mutations in the endogenous gene for the acetyl-CoA carboxylase-2 isoform of acetyl-CoA carboxylase. Inactivation of acetyl-CoA carboxylase-2 results in mice exhibiting a phenotype of reduced malonyl-CoA levels in skeletal muscle and heart, unrestricted fat oxidation, and reduced fat accumulation in the liver and fat storage cells. As a result, the mice consume more food but accumulate less fat and remain leaner than wild type mice fed the same diet. These results demonstrate that inhibition of ACC2 acetyl-CoA carboxylase could be used to regulate fat oxidation and accumulation for purposes of weight control. The transgenic mice of the instant invention provide a useful animal model to identify such inhibitors and for studying the mechanisms of fat metabolism and weight control.Type: ApplicationFiled: December 26, 2000Publication date: August 1, 2002Inventors: Salih J. Wakil, Martin M. Matzuk, Lutfi Abu-Elheiga
-
Publication number: 20020042926Abstract: Ovary-specific proteins O1-180, O1-184 and O1-236, polynucleotides encoding them, antibodies which are immunoreactive with them and vectors and host cells containing O1-180, O1-184 or O1-236 and transgenic mice comprising disruptions of those genes are provided. Also provided are methods for detecting cell proliferative or degenerative disorders of ovarian origin and which are associated with O1-180, O1-184 or O1-236 and for creating transgenic mice comprising disruptions of those genes. Further provided are methods for the evaluation of potential contraceptives using the proteins of the invention, as well as methods for the screening for genetic mutations in signaling pathways that are associated with some forms of human infertility or gynecological cancers, also using the proteins/mRNAs/genes of the invention.Type: ApplicationFiled: April 27, 2001Publication date: April 11, 2002Inventors: Martin M. Matzuk, Pei Wang
-
Patent number: 6306654Abstract: Recombinant materials are provided for the production of the &agr;-glycoprotein hormone subunit. These muteins have utility as antagonists and in altering pharmacokinetic activity of these hormones.Type: GrantFiled: November 19, 1993Date of Patent: October 23, 2001Assignee: Washington UniversityInventors: Irving Boime, Martin M. Matzuk, Jeffrey L. Keene
-
Publication number: 20010007757Abstract: The invention provides recombinant native and mutein forms of human follicle stimulating hormone beta subunit (FSH beta) with characteristic glycosylation patterns which are influential in the metabolic activity of the protein. The invention also provides recombinant mutant forms of the human alpha subunit common to FSH, LH, CG, and TSH, to obtain hormones which also have unique glycosylation patterns. Also provided are recombinant materials to produce these subunits separately or together to obtain complete heterodimeric hormones of regulated glycosylation pattern.Type: ApplicationFiled: December 8, 2000Publication date: July 12, 2001Inventors: Irving Boime, Martin M. Matzuk, Jeffrey L. Keene
-
Patent number: 5712122Abstract: Modified protein pharmaceuticals extended with a CTP unit retain their biological activity and they had extended biological half-lives. The CTP extension represents an amino acid sequence derived from that of positions 112-118 to 145 of human chorionic gonadotropin.Type: GrantFiled: June 7, 1995Date of Patent: January 27, 1998Assignee: Washington UniversityInventors: Irving Boime, Martin M. Matzuk, Jeffrey L. Keene